We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

ELITechGroup

Offers a range of products for in vitro diagnostics in clinical chemistry, hemostasis, microbiology, immunology, and ... read more Featured Products: More products

Download Mobile App





ELITech Group Distributes More Than 3.5 Million COVID-19 Tests and Installs Over 500 PCR Systems Globally

By LabMedica International staff writers
Posted on 19 Aug 2020
Print article
Illustration
Illustration
ELITechGroup Molecular Diagnostics (Puteaux, France) has distributed more than 3.5 million SARS-CoV-2 tests and also installed more than 500 ELITe InGenius polymerase chain reaction (PCR) systems, globally, with over a 100 systems placed since the start of the COVID-19 pandemic.

ELITechGroup has been at the forefront of fighting the COVID-19 outbreak in Europe and has been supplying tests on its ELITe InGenius system since early March in Italy, and other affected countries, such as France, the UK, the Benelux and more. The ELITe InGenius system has been widely used in hospitals and other healthcare settings since 2016, and thanks to its reliability and easy adaptability, ELITechGroup was among the first companies to have SARS-CoV-2 tests on a sample-to-result system. The ELITe InGenius system allows laboratories to reliably detect SARS-CoV-2 in only a few hours, as well as conducting parallel testing for other diseases, such as flu, in order to ensure a correct diagnosis. The fully automated solution can process 12 samples in parallel to deliver results in less than 2.5 hours. This brings several benefits over centralized high-throughput testing approaches as there is no waiting for a large batch of samples to accumulate before testing, and no delays from sending samples off premises to a central laboratory.

By performing extraction, amplification and result interpretation in one device, the ELITe InGenius replaces the multiple devices needed to perform such tasks separately. Full automation also means there is no need for constant supervision, allowing laboratory staff to perform other valuable work. More importantly, the limited hands-on time helps reduce the risk of infection for users. The instrument is straightforward to use, with only minimal training from ELITechGroup's service and support team required. The ELITe InGenius offers the widest molecular diagnostics menu available on a sample-to-result system, with 38 CE-IVD assays dedicated to the individual needs of healthcare settings, be it immuno-compromised patient monitoring; detection of respiratory, gastro-intestinal, sexually transmitted or nosocomial infections; meningitis and encephalitis, as well as diagnostics of genetic factors.

"The continued rapid spread of the novel coronavirus makes it important for every country to test as many patients as possible, as quickly as possible," said ELITechGroup CEO, Christoph Gauer. "We are proud to have played an essential role in equipping healthcare staff with the testing tools they need. We have now expanded our manufacturing capacity to help provide additional ELITe InGenius systems to both new and existing hospitals and laboratories, globally and to support healthcare systems to prepare for the expectedly increasing demand for rapid and reliable diagnostics for all patients."

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.